Osteoporosis Risk Management
Please ensure that the Discussion includes more than 400 words with scholarly articles, and the plagiarism level must remain below 20%.
Answer the following items using your own words. Be objective and concise while being professional.
1. During a case presentation at your clinic, you review four women with predisposing factors for osteoporosis. Which patient is least likely to be at risk for osteoporosis?
A. Nehineza, an African American female with a family history of uterine cancer
B. Cristina, a Hispanic woman living a sedentary life
C. Park-Gim-Ka, an underweight Asian woman with a history of tobacco use
D. Skylar, a Caucasian woman experiencing early onset of menopause.
2. Densitometry results are given as T-scores. Which values would be considered osteopenia?
3. After prompt analysis of your patient, you decide to institute treatment for osteoporosis. Which class of medication is considered the first-line treatment? Are there any considerations to be made prior to starting therapy? Which recommendations would you provide to the patient regarding this treatment?
Check out our Essay writing services
Osteoporosis Risk Management
Least Likely at Risk
Among the patients, Nehineza, an African American female, is least likely to be at risk for osteoporosis. Higher body weight provides mechanical load on bones, which helps in maintaining bone density. African American women also tend to have higher peak bone mass compared to other ethnicities (Gourlay & Brown, 2021). While her family history of uterine cancer may impact overall health, it is not a major direct contributor to osteoporosis risk.
T-Scores and Osteopenia
T-scores from bone densitometry measure standard deviations from the average bone density of a healthy young adult. According to the World Health Organization (WHO), osteopenia is defined as a T-score between -1.0 and -2.5 (Kanis et al., 2019). Values above -1.0 are considered normal, and below -2.5 indicates osteoporosis. Regular monitoring of T-scores is essential for assessing fracture risk and guiding treatment decisions.
First-Line Osteoporosis Treatment
The first-line pharmacologic treatment for osteoporosis is typically bisphosphonates such as alendronate or risedronate. These drugs reduce bone resorption by inhibiting osteoclast activity. Before initiating therapy, clinicians must assess renal function and ensure adequate vitamin D and calcium levels to reduce risks of side effects such as esophageal irritation or atypical fractures (Eastell et al., 2016).
Patient Education and Recommendations
Weight-bearing exercises, smoking cessation, limited alcohol intake, and adequate intake of calcium and vitamin D are essential non-pharmacologic strategies. Continuous follow-up ensures adherence and evaluates treatment efficacy.
